Semaglutide vs Liraglutide
Comparison of two FDA-approved GLP-1 agonists for diabetes and weight management.
Last updated: January 19, 2026
Semaglutide
Liraglutide
Overview
Both are FDA-approved GLP-1 agonists from Novo Nordisk, but semaglutide offers greater efficacy and less frequent dosing.
Key Differences
| Aspect | Semaglutide | Liraglutide |
|---|---|---|
| Max Weight Loss | ~15% (STEP) | ~8% (SCALE) |
| CV Outcomes | SELECT positive | LEADER positive |
Efficacy Comparison
| Metric | Semaglutide 2.4mg | Liraglutide 3.0mg |
|---|---|---|
| Weight Loss | 14.9% | 8.0% |
| HbA1c (T2D) | Superior | Established |
| CV Benefit | 20% MACE reduction | 13% MACE reduction |
Convenience
Semaglutide’s once-weekly dosing offers significant convenience advantage over daily liraglutide injections.
Summary
- Semaglutide: More effective, less frequent dosing
- Liraglutide: First-in-class, longer track record
- Both have established efficacy and CV benefits
This comparison is for educational purposes only. Both medications require a prescription.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.